BioMarin Pharmaceutical Statistics
Total Valuation
BMRN has a market cap or net worth of $12.53 billion. The enterprise value is $12.25 billion.
| Market Cap | 12.53B |
| Enterprise Value | 12.25B |
Important Dates
The last earnings date was Tuesday, October 29, 2024, after market close.
| Earnings Date | Oct 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BMRN has 190.58 million shares outstanding. The number of shares has increased by 0.93% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 190.58M |
| Shares Change (YoY) | +0.93% |
| Shares Change (QoQ) | -1.67% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 94.08% |
| Float | 179.19M |
Valuation Ratios
The trailing PE ratio is 39.00 and the forward PE ratio is 18.14. BMRN's PEG ratio is 0.68.
| PE Ratio | 39.00 |
| Forward PE | 18.14 |
| PS Ratio | 4.54 |
| Forward PS | 4.10 |
| PB Ratio | 2.32 |
| P/FCF Ratio | 39.33 |
| PEG Ratio | 0.68 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.76, with an EV/FCF ratio of 38.30.
| EV / Earnings | 38.02 |
| EV / Sales | 4.45 |
| EV / EBITDA | 28.76 |
| EV / EBIT | 37.54 |
| EV / FCF | 38.30 |
Financial Position
The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.27 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.37 |
| Debt / FCF | 1.88 |
| Interest Coverage | 20.16 |
Financial Efficiency
Return on equity (ROE) is 6.25% and return on invested capital (ROIC) is 3.40%.
| Return on Equity (ROE) | 6.25% |
| Return on Assets (ROA) | 3.00% |
| Return on Capital (ROIC) | 3.40% |
| Revenue Per Employee | $809,412 |
| Profits Per Employee | $94,764 |
| Employee Count | 3,401 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.19 |
Taxes
In the past 12 months, BMRN has paid $69.16 million in taxes.
| Income Tax | 69.16M |
| Effective Tax Rate | 17.67% |
Stock Price Statistics
The stock price has decreased by -17.06% in the last 52 weeks. The beta is 0.31, so BMRN's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | -17.06% |
| 50-Day Moving Average | 74.15 |
| 200-Day Moving Average | 82.59 |
| Relative Strength Index (RSI) | 29.46 |
| Average Volume (20 Days) | 1,382,191 |
Short Selling Information
The latest short interest is 5.59 million, so 2.93% of the outstanding shares have been sold short.
| Short Interest | 5.59M |
| Short Previous Month | 5.28M |
| Short % of Shares Out | 2.93% |
| Short % of Float | 3.12% |
| Short Ratio (days to cover) | 2.64 |
Income Statement
In the last 12 months, BMRN had revenue of $2.75 billion and earned $322.29 million in profits. Earnings per share was $1.68.
| Revenue | 2.75B |
| Gross Profit | 1.44B |
| Operating Income | 326.41M |
| Pretax Income | 298.68M |
| Net Income | 322.29M |
| EBITDA | 426.09M |
| EBIT | 326.41M |
| Earnings Per Share (EPS) | $1.68 |
Balance Sheet
The company has $930.44 million in cash and $602.69 million in debt, giving a net cash position of $327.76 million or $1.72 per share.
| Cash & Cash Equivalents | 930.44M |
| Total Debt | 602.69M |
| Net Cash | 327.76M |
| Net Cash Per Share | $1.72 |
| Equity (Book Value) | 5.41B |
| Book Value Per Share | 28.41 |
| Working Capital | 2.34B |
Cash Flow
In the last 12 months, operating cash flow was $414.70 million and capital expenditures -$94.81 million, giving a free cash flow of $319.89 million.
| Operating Cash Flow | 414.70M |
| Capital Expenditures | -94.81M |
| Free Cash Flow | 319.89M |
| FCF Per Share | $1.68 |
Margins
Gross margin is 52.35%, with operating and profit margins of 11.86% and 11.71%.
| Gross Margin | 52.35% |
| Operating Margin | 11.86% |
| Pretax Margin | 14.22% |
| Profit Margin | 11.71% |
| EBITDA Margin | 15.48% |
| EBIT Margin | 11.86% |
| FCF Margin | 9.30% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.93% |
| Shareholder Yield | -0.93% |
| Earnings Yield | 2.56% |
| FCF Yield | 2.54% |
Analyst Forecast
The average price target for BMRN is $94.45, which is 43.67% higher than the current price. The consensus rating is "Buy".
| Price Target | $94.45 |
| Price Target Difference | 43.67% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (5Y) | 12.21% |
| EPS Growth Forecast (5Y) | 51.73% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BMRN has an Altman Z-Score of 7.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.71 |
| Piotroski F-Score | 6 |